Johns Hopkins researchers published findings demonstrating that pharmaceutical companies were systematically gaming the 1983 Orphan Drug Act by obtaining orphan drug designations—intended for treatments of rare diseases affecting fewer than 200,000 Americans—for blockbuster drugs generating billions …
Johns Hopkins UniversityFDAAbbVieRocheJohnson & Johnson+4 morepharmaceutical-industryregulatory-capturetax-avoidancedrug-pricinghealthcare+2 more
Valeant Pharmaceuticals’ October 2015 disclosure of its relationship with specialty pharmacy Philidor Rx Services triggered the unraveling of a systematic drug price gouging scheme that had raised prices on dozens of medications by 50-3000% over two years. Under CEO Michael Pearson, Valeant …
Valeant PharmaceuticalsJ. Michael PearsonPhilidor Rx ServicesWilliam AckmanSecurities and Exchange Commission (SEC)+2 morepharmaceutical-industrydrug-pricinghealthcarecorporate-fraudsystematic-corruption+1 more
The Supreme Court ruled 5-3 in FTC v. Actavis that the Federal Trade Commission could bring antitrust challenges against “pay-for-delay” agreements where brand-name drug manufacturers pay generic competitors to delay bringing cheaper alternatives to market. The decision reversed lower …
Supreme Court of the United StatesFederal Trade CommissionSolvay PharmaceuticalsActavisWatson Pharmaceuticals+1 morepharmaceutical-industrypatent-abuseregulatory-captureantitrustsupreme-court+2 more
Questcor Pharmaceuticals implemented an overnight price increase for H.P. Acthar Gel from $1,600 to $23,000 per vial on August 27, 2007, launching a decade-long price gouging scheme that would eventually raise the drug’s price by 97,000% from its 2001 level. Questcor had acquired Acthar—a …
Questcor PharmaceuticalsMallinckrodtFederal Trade CommissionHumanaCongress+1 morepharmaceutical-industrydrug-pricinghealthcarecorporate-fraudbribery+2 more
The average price of insulin in the United States began a decade-long tripling from $231 per patient annually in 2002 to $762 in 2013, according to congressional hearing data—with some patients paying up to $900 per month for insulin products that cost $4.34 per milliliter in 2002 but reached $12.92 …
Eli LillyNovo NordiskSanofiCongressional Diabetes CaucusBig Pharmapharmaceutical-industrydrug-pricinghealthcaremonopolyinsulin-crisis+1 more